Time to capitalise on Hikma’s ongoing (share price) momentum
17/05/24 -"We have incorporated higher royalty payments in 2024 related to the sale of the generic version of sodium oxybate (medicine to treat symptoms of narcolepsy, i.e. sudden muscle weakness and excessive ..."
Pages
53
Language
English
Published on
17/05/24
You may also be interested by these reports :
19/06/26
Evaluating Pharma’s Defences
17/06/26
Our target price is reduced to CHF94 (from CHF97) on the back of a lower sales base. We have also adjusted forward years’ growth, slightly increasing ...
15/06/26
The target price is upgraded on the back of higher margins in 2026. The EBITDA margin is lifted from 15.4% to 17.9% for the full year (guidance is ...
09/06/26
Our estimates for 2026-2027 have been revised downward following the reclassification of Capsules & Health Ingredients (CHI) as discontinued ...